The anti-Ly6E-CBI conjugate shows substantial inhibition of xenograft growth after a single dose, and in contrast to MMAE conjugates, repeated doses resulting in partial tumor regression do not lead to substantial tumor outgrowth. Here, LY6E is linked to neoplasm.